Real‐world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey

• Published in: International journal of urology 2024-08, Vol.31 (8), p.933-943
• Main Authors: Cheng, Li‐Jen, Kim, Janet, Mukherjee, Apurba, Milloy, Neil, Unsworth, Mia, Ng, Daniel
• Format: Article
• Language: English
• Subjects: Apoptosis; Cancer; Cell death; Chemotherapy; Ligands; Metastases; Metastasis; metastatic; Original; Original : Laboratory Investigation; Pain; Patients; PD-1 protein; Public health; Quality of life; Questionnaires; Standard deviation; treatment patterns; Urothelial carcinoma
• ISSN: 0919-8172; 1442-2042; 1442-2042
• DOI: 10.1111/iju.15497

Objectives To evaluate demographic and clinical characteristics, treatment patterns, and quality of life in patients with locally advanced or metastatic urothelial carcinoma in Asia. Methods Data were drawn from the Adelphi Real World Metastatic Urothelial Carcinoma Disease Specific Programme™, a cross‐sectional survey of medical oncologists/urologists and their adult patients in Saudi Arabia, South Korea, Taiwan, and Turkey. Exploratory patient‐reported outcomes included the EQ‐5D visual analog scale, European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health, and Brief Pain Inventory. Analyses were descriptive. Results Overall, 175 physicians reported data for 988 patients. Mean (standard deviation) patient age was 66.3 (10.8) years, 77% were men, and 82% had bladder tumors at diagnosis. Of patients receiving first‐ (n = 988), second‐ (n = 290), and third‐line (n = 87) treatments, 81%, 35%, and 59% received chemotherapy, respectively, and 17%, 63%, and 34% received programmed cell death protein 1/ligand 1 inhibitors, respectively. Patient‐reported (n = 319) mean (standard deviation) EQ‐5D visual analog scale score was 51.8 (15.6), European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health status score was 44.6 (19.9), and Brief Pain Inventory score was 6.5 (1.9; n = 315). Conclusion The most common first‐ and second‐line treatments for locally advanced or metastatic urothelial carcinoma were chemotherapy and programmed cell death protein 1/ligand inhibitors, respectively. At third line, 10% of patients received best supportive care alone, underscoring an unmet need for effective third‐line treatment options. Patients in all regions reported quality‐of‐life impairment.